指南与共识妇科

晚期卵巢癌指南不依从原因的老少差异

Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.
指南 / 共识 · Gynecol Oncol · 2020-03-11

基于荷兰癌症登记处2015-2018年4210例FIGO IIb-IV期卵巢癌女性,分析指南不依从的治疗模式及原因是否随年龄不同。随年龄增长,指南依从治疗比例从<65岁的70%降至≥85岁的2%,仅支持治疗从4%升至69%。老年女性最常见不依从原因为患者偏好,年轻女性为功能状态和疾病范围。

要点

  • 年龄越大指南依从治疗越少,≥85岁仅2%接受指南依从治疗。
  • 老年女性不依从主因是患者偏好,年轻女性为功能状态和疾病范围。
  • 需重视 eliciting 患者治疗偏好并促进共享决策。

核心结论

  • 多数老年晚期卵巢癌女性未接受指南依从治疗,患者偏好是最常见原因。

研究设计与样本

  • 基于荷兰癌症登记处2015-2018年FIGO IIb-IV期卵巢癌女性4210例的回顾性分析。

主要发现

  • 年龄<65、65-75、75-85、≥85岁分别占34%、33%、26%、8%。
  • 指南依从治疗比例从<65岁的70%降至≥85岁的2%。
  • 仅支持治疗比例从<65岁的4%升至≥85岁的69%。
  • 老年女性不依从最常见原因为患者偏好,年轻女性为功能状态和疾病范围。

临床怎么用

  • 临床决策时应主动询问并记录患者治疗偏好,尤其对老年患者。
  • 对年轻患者需评估功能状态和疾病范围以解释不依从原因。

局限性

  • 需前瞻性研究探究女性拒绝指南治疗的动机及共享决策的影响程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aims to assess the reasons for guideline non-adherence in women with advanced stage ovarian cancer and whether these reasons differ according to age. METHODS: All women diagnosed with advanced stage ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) IIb-IV, between 2015 and 2018 were selected from the Netherlands Cancer Registry. Treatment patterns and reasons for guideline non-adherence were analyzed according to age groups. RESULTS: 4210 women were included, of whom 34%, 33%, 26%, and 8% were aged <65, 65-75, 75-85, and ≥85 years respectively. With advancing age, less women received guideline-adherent treatment (decreasing from 70% to 2% in women aged <65 and ≥85 years respectively) and more women received best supportive care only (ranging from 4% to 69% in women aged <65 and ≥85 years respectively). The most prevalent reasons for guideline non-adherence differed according to age and included patient preference in older women, and functional status and extent of disease in younger women. CONCLUSIONS: Most older women did not receive guideline-adherent care and patient preference was the most common reason for this decision. This knowledge provides insight in the current treatment decision-making process and highlights the importance of eliciting patient treatment preferences. Further prospective research is necessary to study the underlying motivation for women to decline guideline care and the extent to which shared decision-making influences treatment choice.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. van Walree IC, Bretveld R, van Huis-Tanja LH, et al. Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer. Gynecol Oncol. 2020. PMID: 32171566. doi:10.1016/j.ygyno.2020.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。